Hyloris Pharmaceuticals (LTS:0AB6) Short Interest


LTS:0AB6 Hyloris Pharmaceuticals SA LTS:0AB6
63 GF Score
Price €4.52
GF Value €9.49
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0AB6 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Short Interest falls into.


LTS:0AB6
63GF Score
Hyloris Pharmaceuticals SA LTS:0AB6
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.52 is trading 52.4% below its estimated GF Value™ of €9.49. GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LTS:0AB6:

  • Short Interest:
  • GF Value™: €9.49 vs. price of €4.52 (52.4% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Other Exchanges 52U:GermanyHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
63GF Score

Get the complete analysis for LTS:0AB6

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.52
Price
€9.49
GF Value